SBP-7455是一种针对 ULK1/ULK2 的自噬抑制剂，对三阴性乳腺癌等癌症研究具有重要的应用前景。

BL-918 is an orally active UNC-51-like kinase 1 (ULK1) activator with an EC50 of 24.14 nM. BL-918 induces cytoprotective autophagy for Parkinson's disease treatment.

LK-101 is a potent and selective ULK1 inhibitor with in vitro IC50 of 8.3 nM.

SBI-0206965是一种高效、选择性、细胞渗透性 ULK1 激酶抑制剂，对 ULK1 激酶的 IC50 为 108 nM，对密切相关的激酶 ULK2 的 IC50 为 711 nM。

MRT68921 是一种有效的 ULK1 和 ULK2 抑制剂，IC50 值分别为 2.9 nM 和 1.1 nM。

MRT68921 HCl is a selective inhibitor of ULK1 and ULK2 with IC50 0f 2.9 nM and 1.1 nM.

LYN-1604 is a potent UNC-51-like kinase 1 (ULK1) agonist with an EC50 of 18.94 nM.

MRT68921 dihydrochloride is the most potent inhibitor of ULK1 and ULK2, with IC50 values of 2.9 nM and 1.1 nM, respectively.

LYN-1604 HCl is an agonist of ULK1 with EC50 of 18.94 nM.

MRT67307 HCl is a potent and dual IKKε and TBK1 inhibitor with IC50 of 160 and 19 nM, respectively.

LYN-1604 dihydrochloride is a potent UNC-51-like kinase 1 (ULK1) activator (EC50=18.94 nM) for the research of triple negative breast cancer (TNBC)[1].

MRT67307 HCl is a potent and dual IKKε and TBK1 inhibitor.